Stock of the Day

October 14, 2019

Qiagen (QGEN)

$41.19
-$0.32 (-0.8%)
Market Cap: $8.55B

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

Today's Trend

Qiagen N.V. (NYSE: QGEN) is under pressure after a combination of weaker forward earnings expectations and a reduced growth outlook overshadowed a few supportive business updates. The stock has been moving lower as investors react to signs that near-term growth may be slower than previously expected, even though management still points to solid margins and cash generation.

Bottom line: Qiagen N.V. (NYSE: QGEN) is trading down mainly because investors are focusing on the lower 2026 outlook and Q1 miss, while analyst estimate cuts reinforce the caution. Offseting factors like new product launches and strong cash generation may help, but they are not enough right now to outweigh the near-term growth concerns.

Recent News